Lyra Therapeutics, Inc.
LYRA
$0.73
-$0.01-1.22%
OTC PK
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -16.16% | 19.54% | 12.99% | 22.15% | 7.53% |
| Total Depreciation and Amortization | -3.85% | -18.11% | -0.78% | -15.23% | 287.18% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 1,552.94% | -96.25% | 9.82% | -50.66% | 53.39% |
| Change in Net Operating Assets | 114.72% | -714.52% | 85.10% | 43.17% | 59.92% |
| Cash from Operations | 17.59% | -11.70% | 25.47% | 22.11% | 30.03% |
| Capital Expenditure | -- | 100.00% | -- | -- | 213.73% |
| Sale of Property, Plant, and Equipment | -- | -100.00% | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | 242.69% |
| Cash from Investing | -- | 100.00% | -- | -- | 245.55% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -- | -100.00% | -- | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 100.00% | -2.79% | -- | -- | 100.00% |
| Cash from Financing | 100.00% | -107.93% | -- | -- | 95.65% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 20.27% | -296.16% | 77.93% | -152.70% | 307.01% |